survival in our population. We therefore set out to examine the demographic distribution of our patient population and impact of these factors on morbidity and mortality. Patients and Methods: We examined retrospectively the outcome of 44 consecutive patients (30 males, 14 females) with Hodgkin's and Non-Hodgkin's lymphoma (HL, NHL) who were seen at our hospital between 04/1999 and 02/2006. Results: The median age was 33 years (range, 4 73). Of the patients with HL (n = 14, 32%); four (29%), five (36%) and four (29%) respectively had lymphocyte predominant, mixed cellularity and nodular sclerosis while seven (23%) and 24 (77%) of those with NHL (n = 30, 68%) had low-grade and high-grade histology. At presentation 31 of 33 (94%) patients were clinically advanced (stage < 3). Two of the 25 patients screened for HIV antibodies were reactive. All patients were scheduled to receive chemotherapy. COPP (cyclophosphamide, vincristine, procarbazine and prednisolone; 2 6 cycles) was administered to 11 patients with HL while one had ABVD (doxorubicin, bleomycin, vinblastine and darcabazine). Most of those with NHL had 1 8 cycles of either CVP (cyclophosphamide, vincristine and prednisolone; n = 8) or CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone; n = 18). Three paediatric patients with aggressive NHL had either COM (cyclophosphamide, vincristine and methotrexate, plus intrathecal therapy; n = 2) or COAP (cyclophosphamide, vincristine, cytosine arabinoside and methotrexate). Overall, 24 (59%) patients had between one and five cycles while 17 (41%) had six or more cycles of chemotherapy. As of February 2006, 33 patients (79%) remain alive after a median follow-up of 133 days (range, 2 1196) post-therapy; with 9 having died. Overall survival (OS) at 3 years after treatment was 66%. Kaplan Meier univariate analysis showed a survival advantage of HL over NHL, female over male sex and 6 over <6 chemotherapy cycles. Conclusion: Our data suggests that despite high default rates, up to 79% short-term survival can be achieved in patients with clinically advanced malignant lymphoma in developing countries. Results are likely to improve with earlier presentation, lower default rates and improvements in chemotherapy support services.